◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › B › BMY

Bristol-Myers Squibb Company (BMY) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · Pharmaceuticals · DATA UPDATED 2026-08-16

Bristol-Myers Squibb Company (BMY) operates in the Pharmaceuticals industry and is headquartered in Princeton, United States with about 32,500 employees. Its market capitalization is roughly $129 billion. In the fiscal year ended 2025-12-31, BMY reported $48.2B in revenue and $7.1B in net income.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications.

Interactive charts & full statements → Open the BMY valuation workbench →

BMY Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$49.2B	$48.2B	$48.3B	$45.0B	$46.2B	$46.4B	$42.5B	$26.1B	$22.6B	$20.8B	$19.4B	$16.6B	$15.9B	$16.4B	$17.6B	$21.2B	$19.5B	$18.8B	$20.6B	$19.3B	$17.9B
Gross Profit	$34.5B	$34.3B	$27.4B	$25.4B	$26.5B	$26.8B	$21.7B	$17.2B	$16.1B	$15.0B	$14.5B	$12.8B	$12.0B	$11.8B	$13.2B	$15.7B	$14.3B	$13.8B	$14.4B	$13.2B	$11.7B
Gross Margin %	70.2%	71.1%	56.8%	56.3%	57.4%	57.7%	51.0%	66.0%	71.2%	72.0%	74.6%	77.3%	75.6%	72.0%	74.8%	74.0%	73.6%	73.2%	70.1%	68.3%	65.2%
Operating Income (EBIT)	$13.9B	$13.7B	$9.7B	$8.5B	$9.3B	$9.5B	$4.5B	$6.4B	$6.4B	$5.2B	$5.2B	$3.9B	$3.1B	$3.1B	$4.3B	$6.8B	$6.1B	$5.0B	$4.9B	$3.8B	$2.6B
Operating Margin %	28.3%	28.5%	20.0%	18.8%	20.1%	20.6%	10.6%	24.6%	28.3%	25.2%	26.7%	23.8%	19.7%	19.1%	24.2%	31.8%	31.5%	26.8%	23.7%	19.5%	14.8%
Net Income	$9.3B	$7.1B	($8.9B)	$8.0B	$6.3B	$7.0B	($9.0B)	$3.4B	$4.9B	$1.0B	$4.5B	$1.6B	$2.0B	$2.6B	$2.0B	$3.7B	$3.1B	$10.6B	$5.2B	$2.2B	$1.6B
Net Margin %	18.9%	14.6%	-18.5%	17.8%	13.7%	15.1%	-21.2%	13.2%	21.8%	4.9%	22.9%	9.4%	12.6%	15.6%	11.1%	17.5%	15.9%	56.4%	25.5%	11.2%	8.8%
EBITDA	$16.7B	$15.2B	$3.2B	$19.4B	$19.2B	$20.1B	$4.9B	$7.4B	$6.8B	$6.1B	$6.5B	$2.6B	$3.1B	$3.9B	$3.2B	$7.8B	$6.8B	$6.5B	$5.9B	$4.4B	$3.3B
Earnings Per Share (EPS)	$4.54	$3.46	$-4.41	$3.86	$2.95	$3.12	$-3.98	$2.01	$3.01	$0.61	$2.65	$0.93	$1.20	$1.54	$1.16	$2.16	$1.80	$5.37	$2.62	$1.09	$0.81
Shares Outstanding (M)	2,048M	2,041M	2,027M	2,078M	2,146M	2,245M	2,258M	1,712M	1,637M	1,652M	1,680M	1,679M	1,670M	1,662M	1,688M	1,717M	1,727M	1,978M	2,001M	1,980M	1,963M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BMY Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$13.0B	$11.5B	$12.5B	$12.2B	$12.3B	$11.2B	$12.3B	$11.9B
Gross Profit	$9.2B	$8.1B	$8.4B	$8.8B	$8.9B	$8.2B	$7.4B	$6.6B
Gross Margin %	71.3%	70.2%	67.2%	71.9%	72.5%	72.9%	60.2%	55.6%
Operating Income (EBIT)	$4.1B	$3.4B	$2.8B	$3.6B	$3.8B	$3.5B	$2.5B	$2.3B
Operating Margin %	31.5%	29.3%	22.5%	29.8%	30.8%	31.2%	20.5%	19.2%
Net Income	$3.3B	$2.7B	$1.1B	$2.2B	$1.3B	$2.5B	$72M	$1.2B
Net Margin %	25.6%	23.3%	8.7%	18.0%	10.7%	21.9%	0.6%	10.2%
EBITDA	$4.9B	$4.2B	$2.9B	$4.6B	$3.3B	$4.5B	$2.6B	$4.8B
Earnings Per Share (EPS)	$1.62	$1.31	$0.53	$1.08	$0.64	$1.21	$0.04	$0.60
Shares Outstanding (M)	2,048M	2,044M	2,041M	2,038M	2,038M	2,037M	2,037M	2,031M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BMY Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	$12.8B	$14.2B	$15.2B	$13.9B	$13.1B	$16.2B	$14.1B	$8.1B	$7.1B	$5.3B	$3.1B	$2.1B	$3.1B	$3.5B	$6.9B	$4.8B	$4.5B	$4.1B	$3.7B	$3.2B	$2.1B
Capital Expenditures (CapEx)	$1.3B	$1.3B	$1.2B	$1.2B	$1.1B	$973M	$753M	$836M	$951M	$1.1B	$1.2B	$820M	$526M	$537M	$548M	$367M	$424M	$730M	$941M	$843M	$793M
Free Cash Flow (FCF)	$11.4B	$12.8B	$13.9B	$12.7B	$11.9B	$15.2B	$13.3B	$7.2B	$6.1B	$4.2B	$1.8B	$1.3B	$2.6B	$3.0B	$6.4B	$4.5B	$4.1B	$3.3B	$2.8B	$2.3B	$1.3B
FCF Margin %	23.3%	26.7%	28.9%	28.1%	25.9%	32.8%	31.3%	27.7%	27.1%	20.3%	9.5%	7.8%	16.5%	18.4%	36.3%	21.1%	20.9%	17.7%	13.4%	11.9%	7.2%
Dividends Paid	$5.1B	$5.0B	$4.9B	$4.7B	$4.6B	$4.4B	$4.1B	$2.7B	$2.6B	$2.6B	$2.5B	$2.5B	$2.4B	$2.3B	$2.3B	$2.3B	$2.2B	$2.5B	$2.5B	$2.2B	$2.2B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BMY Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	$3.4B	$1.1B	$2.0B	$6.3B	$3.9B	$2.0B	$4.4B	$5.6B
Capital Expenditures (CapEx)	$305M	$347M	$370M	$320M	$361M	$260M	$378M	$324M
Free Cash Flow (FCF)	$3.1B	$757M	$1.6B	$6.0B	$3.6B	$1.7B	$4.1B	$5.3B
FCF Margin %	23.8%	6.6%	12.8%	49.0%	29.0%	15.1%	32.9%	44.3%
Dividends Paid	$1.3B	$1.3B	$1.3B	$1.3B	$1.3B	$1.3B	$1.2B	$1.2B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BMY Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$87.6B	$90.0B	$92.6B	$95.2B	$96.8B	$109.3B	$118.5B	$129.9B	$35.0B	$33.6B	$33.7B	$31.7B	$33.7B	$38.6B	$35.9B	$33.0B	$31.1B	$31.0B	$29.5B	$26.2B	$25.6B
Cash & Cash Equivalents	$8.7B	$10.2B	$10.3B	$11.5B	$9.1B	$14.0B	$14.5B	$12.3B	$6.9B	$5.4B	$4.2B	$2.4B	$5.6B	$3.6B	$1.7B	$5.8B	$5.0B	$7.7B	$8.0B	$1.8B	$2.0B
Total Liabilities	$65.3B	$71.5B	$76.2B	$65.7B	$65.7B	$73.3B	$80.6B	$78.2B	$20.9B	$21.7B	$17.4B	$17.3B	$18.8B	$23.4B	$22.3B	$17.1B	$15.4B	$16.2B	$17.3B	$15.6B	$15.6B
Total Debt (Short + Long-Term)	$43.1B	$45.3B	$49.8B	$39.9B	$39.5B	$44.7B	$50.8B	$46.9B	$7.3B	$8.0B	$6.7B	$6.7B	$7.8B	$8.3B	$7.4B	$5.5B	$5.4B	$6.4B	$6.7B	$6.3B	$7.4B
Total Shareholders' Equity	$22.3B	$18.5B	$16.3B	$29.4B	$31.1B	$35.9B	$37.8B	$51.6B	$14.0B	$11.7B	$16.2B	$14.3B	$14.9B	$15.2B	$13.6B	$16.0B	$15.7B	$14.8B	$12.2B	$10.6B	$10.0B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive BMY viewer.

BMY Metric Deep Dives

Other Companies in Pharmaceuticals

LLY · Lilly (Eli) — $1.03 trillion
JNJ · Johnson & Johnson — $651 billion
MRK · Merck & Co. — $362 billion
PFE · Pfizer — $158 billion
ZTS · Zoetis — $30 billion
VTRS · Viatris — $19 billion

This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी

← BMWVENTLTD All “B” companies BN →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.